We can’t show the full text here under this license. Use the link below to read it at the source.
CADD based designing and biological evaluation of novel triazole based thiazolidinedione coumarin hybrids as antidiabetic agent
Computer-designed new triazole-thiazolidinedione-coumarin compounds tested as diabetes treatments
AI simplified
Abstract
Compound I-1 demonstrated an IC value of 1.49 µg/ml against the α-glucosidase enzyme.
- Molecular docking studies indicated that Compound I-1 is a promising scaffold for drug design targeting α-glucosidase.
- In vivo studies showed that Compound I-1 significantly lowered blood glucose levels to 94.15 mg/dL and 74.60 mg/dL at doses of 10 mg/kg and 20 mg/kg, respectively.
- Compounds I-1 resulted in significant reductions in liver and kidney function markers, including ALT, AST, ALP, urea, LDH, and creatinine levels.
- Pharmacokinetic evaluations suggested favorable drug-likeness and ADMET properties for Compound I-1.
- Density functional theory analyses provided insights into the stability and reactivity of Compound I-1 as a diabetes treatment candidate.
AI simplified
Key numbers
1.49 µg/ml
of Compound I-1
In vitro α-glucosidase inhibition assay results
94.15 mg/dL
Blood glucose levels at 10 mg/kg
In vivo antidiabetic activity study results
74.60 mg/dL
Blood glucose levels at 20 mg/kg
In vivo antidiabetic activity study results